Health & Fitness
Health and Fitness
Health and Fitness
Tue, February 24, 2009
Mon, February 23, 2009 Acrongenomics? Business Associate Molecular Vision Ltd Appoints Peter Woodford as Chairman
LONDON--([ BUSINESS WIRE ])--Acrongenomics, Inc. (OTCBB:AGNM) is pleased to announce today that its business associate Molecular Vision Limited, an Imperial College London spin-out company developing quantitative point-of-care (POC) diagnostic devices, has appointed Peter Woodford as Non-Executive Chairman. The appointment serves to strengthen the board as Molecular Vision prepares to commercialise its novel detection technology, focusing on low cost POC diagnostic tests in a miniaturised, easy-to-use, disposable format.
Mr Woodford has over 35 years' experience in the diagnostics industry. Most recently he spent 15 years with Roche Diagnostics/Boehringer Mannheim, where he was responsible for all global strategic and commercial activities at Roche Diabetes Care, a £1.2 billion business.
Commenting on the appointment, Dr Ian Campbell, CEO, Molecular Vision, said "We are delighted to attract someone of Peter's calibre. His extensive experience and expertise of the global diagnostics industry perfectly complement the range of skills offered by the existing members of the Board."
Mr Woodford commented: "I am excited by the clear potential of Molecular Vision's technology platform, and look forward to working with the team as we move towards commercialisation."
Peter Woodford's appointment follows that of Dr Simon Rattle, who joined Molecular Vision as Chief Technology Officer in July 2008. Dr Rattle has over 25 years in the diagnostics industry, having held R&D and Operations positions at senior management and board level within organisations such as Serono Diagnostics Ltd, Anagen (UK) Limited and most recently Genosis PLC. He has a proven record in taking early stage diagnostic companies through the development, manufacturing, quality and regulatory processes into commercialisation.
Dr Evan Manolis, Chairman, Acrongenomics, said: "As one of the major Molecular Vision shareholders, we welcome and salute the appointment of Peter Woodford as chairman of the company. I strongly believe Mr Woodford's know-how and proven competence will assure further progress and solid advancement towards the commercialisation of the technology. Furthermore, I take his interest and enthusiasm for the technology as an extra validation for our investment in Molecular Vision."
Acrongenomics, Inc. is also pleased to announce that it has embarked on another project with a view to developing a new substance to control low density lipoprotein (LDL) and triglycerides in blood. This project will run in tandem with the Molecular Vision projects, adding value and further potential of future income to the Acrongenomics pipeline.
About Acrongenomics Inc.
Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications. The company has its headquarters in London, England.
About Molecular Vision Limited
Molecular Vision is developing low cost easy-to-use microfluidic devices for medical testing that will greatly extend the in-house tools available to the general practitioner. The devices are being developed to allow near patient quantitative diagnosis, currently focusing on key areas of high disease burden, namely kidney function and cardiovascular disease. The technology has additional potential applications outside the diagnostics market, including forensic science, homeland security and environmental monitoring.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements. Forward-looking statements in this document include that we are developing a new substance to control low density lipoprotein (LDL) and triglycerides in blood; that such project adds value and further potential of future income to the Acrongenomics pipeline; and that Molecular Vision can commercialise its novel detection technology. A number of factors may affect and cause those results to differ materially from those indicated. Such factors include our limited operating history; Molecular Vision's need for significant capital to finance internal growth as well as strategic acquisitions; its ability to attract and retain key employees and strategic partners; its and our ability to achieve and maintain profitability; competition from other providers of similar products and services; the possible unacceptability of our or Molecular Vision's products by health care authorities and/or practitioners; and other unanticipated future events and conditions. For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.
